Citations

Clear

24 citation(s) found for "Ng, Siew C".

IRAP deficiency preserves renal function and attenuates pathology in aged mice
Ansari, Aneesa , Mirabito Colafella, Katrina M., Hilliard Krause, Lucinda M., Barsha, Giannie , Kett, Michelle M., Garovic, Vesna D. , Denton, Kate M. , Denton, Kate M , Walton, Sarah L. , Colafella, Katrina M. Mirabito , Hilliard, Lucinda M. , Chai, Siew Yeen

Mayo Clinic

Clinical Science | September 3, 2026 | Volume: 140 | Issue: 10 | Pages: 2035-2051

10.1042/cs20261576 | PMID 42690146 Get It

Abstract Senescent cell accumulation and fibrosis play a fundamental role in kidney ageing. Our aim was to determine whether the angiotensin IV/insulin-regulated aminopeptidase (IRAP) axis of the renin-angiotensin system contributes to renal function decline, fibrosis, and senescent cell accumulation in aged mice. We studied the role of IRAP in kidney ageing using IRAP knockout (KO) mice, as well as in wild-type (WT) mice treated with an IRAP inhibitor. Complementary proximal tubule and collecting duct cell models were used to determine the mechanisms by which IRAP inhibition exerts protective effects. Glomerular filtration rate (GFR) declined by 25% in WT mice between 3 and 23 months of age, concomitant with marked increases in albumin excretion, glomerulosclerosis, tubulointerstitial fibrosis, and accumulation of senescent cells in the proximal tubules of the kidney. IRAP KO mice were protected against age-related decline in GFR, renal fibrosis, and senescence burden compared with age-matched WT mice. IRAP inhibition for 4 weeks (HFI-419, 500 ng/kg/min) in 28-month-old WT mice similarly prevented age-related decline in GFR and attenuated expression of cellular senescence markers. Using an in vitro model of cultured proximal tubule cells, IRAP inhibition mitigated the pro-senescent effects of oxidative stress. This was associated with shifts in the metabolic phenotype of proximal tubular cells, indicating the senoprotective effects of IRAP inhibition may be mediated in part via mitochondrial function. These studies provide evidence that IRAP deficiency is protective against chronic renal cellular senescence, fibrosis, and functional decline. Therefore, IRAP inhibition has therapeutic potential to attenuate pathological cardiorenal ageing through senoprotective mechanisms.
Accelerating Evidence-Based Practices in Acute Kidney Injury
Brown, Jeremiah R. , Rabin, Borsika A. , Akcan‐Arikan, Ayse , Awdishu, Linda , Bagshaw, Sean M. , Brookman‐Frazee, Lauren , Cerdá, Jorge , Granado, Rolando Claure‐Del , Ghazi, Lama , Goldstein, Stuart L. , Liu, Kathleen D., Mottes, Theresa, Selby, Nicholas M. , Vijaykumar, Aarthi, Zarbock, Alexander, Neyra, Javier A. , Rewa, Oleksa G , Rabin, Borsika A , Akcan-Arikan, Ayse , Awdishu, Linda , Bagshaw, Sean M , Brookman-Frazee, Lauren , Cerdá, Jorge , Claure-Del Granado, Rolando , Ghazi, Lama , Goldstein, Stuart L , Jeong, Rachel , Kashani, Kianoush B , Koyner, Jay L , Macedo, Etienne , Pannu, Neesh , Reddy, Yuvaram N V , See, Emily , Selby, Nicholas M , Siew, Edward D , Silver, Samuel A , Srinsawat, Nattachai , Stadnick, Nicole A , Vijaykumar, Aarthi , Wald, Ron , Wilson, F Perry , Ronco, Claudio , Ostermann, Marlies , Mehta, Ravindra L , Neyra, Javier A , Kashani, Kianoush , Koyner, Jay L. , Liu, Kathleen D. , Macedo, Etienne , Mottes, Theresa , Pannu, Neesh , Reis, Thiago , Siew, Edward D. , Silver, Samuel A. , Wilson, F. Perry , Zarbock, Alexander , Ronco, Claudio , Ostermann, Marlies , Mehta, Ravindra L.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2215/cjn.0000001205 | PMID 42537020 Get It

Scientific evidence regarding AKI and acute kidney care has advanced in recent years. However, a knowledge gap remains on the implementation of these evidence-based practices (EBPs) into clinical care. Implementation science (IS) is focused on ensuring that this knowledge is translated in an effective, efficient and sustainable fashion. Objectives: 1) Define the current status of IS; 2) Define a roadmap for accelerating IS with a focus on patient/care partner advocacy, digital tool application, social determinants of health, and resource-limited settings; and 3) Develop a robust and broad research agenda incorporating IS methodology into the programs. Evidence Review: ADQI XXXV was conducted through a modified Delphi process with virtual meetings preceding an in-person meeting. Five workgroups were determined a priori to focus on 1) IS definitions and methods applicable to AKI and acute kidney care; 2) IS literature in AKI and acute kidney care; 3) Innovations in IS to accelerate the adoption, adherence to, and sustainment of EBPs in AKI and acute kidney care; 4) IS methods in resource-limited settings; and 5) Recommendations to identify and evaluate EBPs that are ready for implementation or de-implementation. Prior to the in-person meeting, each workgroup met virtually to review the literature and develop framework questions to address their objectives. During the two-day in person meeting, through iterative discussions, questions and supporting statements were finalized. These questions and statements were agreed upon through voting to achieve consensus, defined as agreement of ≥80%. Conclusions and Relevance: We report a structured multidisciplinary consensus for defining the role of IS in AKI and acute kidney care. Future programs should address these consensus questions and apply these statements along with IS methodology in the translation of science into clinical practice and the implementation/de-implementation of EBPs in clinical care.
Standardization of Lesion Classification and Assessment by Investigators in Clinical Trials for Hidradenitis Suppurativa
Garg, Amit , Strunk, Andrew , Midgette, Bria, Frasier, Kelly , Cohn, Erica, Aarts, Pim , Alhusayen, Raed , Bechara, Bitte Falk G., Brassard, Alain, Brown, Debra, Emtestam, Lennart , Benhadou, Farida , Fernández‐Peñas, Pablo , Gebauer, Kurt , Horváth, Barbara , Marzano, Angelo Valerio , Orenstein, Lauren A.V. , Pascual, J.C. , Piguet, Vincent, Resnik, Barry I., Roth, Gretchen M. , Straalen, Kelsey van, Ingram, John R , Ingram, J R , Garg, Amit, Cohn, Erica, Alavi, Afsáneh , Bettoli, Vincenzo , Chandran, Nisha Suyien , Choon, Siew Eng , Cohen, Steven R. , Daveluy, Steven , Mármol, V. del , Dellavalle, Robert Paul , Flowers, Richard Hal , Frew, John W. , Giamarellos‐Bourboulis, Evangelos J. , Goldfarb, Noah , Hsiao, Jennifer L. , Jemec, Gregor B. E. , Lowes, Michelle A , Matusiak, Łukasz , Micheletti, Robert , Oon, Hazel H. , Ortega‐Loayza, Alex G. , Paek, So Yeon , Rosmarin, David M. , Sayed, Christopher J. , Silva, Dimitri Luz Felipe da , Thorlacius, Linnea , Tzellos, Thrasyvoulos , Zee, Hessel H. van der , Straalen, Kelsey R. van , Ingram, John R.

Mayo Clinic

JAMA Dermatology | November 26, 2025 | Volume: 162 | Issue: 1 | Pages: 72

10.1001/jamadermatol.2025.4652 | PMID 41296358 Get It

Importance Accurate classification and reliability in assessment for lesions of hidradenitis suppurativa (HS) by investigators is critical to the determination of responder status and to overall data quality in clinical trials. Objective To establish consensus-based morphological definitions of HS lesions and guidance statements that standardize investigator lesion assessments for implementation in clinical trials. Evidence Review Health professionals (primarily dermatologists) with expertise in the measurement of HS disease activity as well as novice raters completed a preliminary questionnaire in which participants were asked to assess images of HS lesions and provide qualitative feedback on their decision making. Based on this feedback, detailed morphologic definitions for lesions and guidance statements that standardize lesion assessments were formulated and presented for consensus voting in 2 electronic Delphi surveys. A virtual group discussion after round 1 supported participants in round 2 voting. Findings Response rates were 84.7% (50 of 59), 86.0% (43 of 50), and 90.9% (40 of 44) in the preliminary, electronic Delphi round 1, and electronic Delphi round 2 surveys, respectively. Morphological definitions for 11 lesion types achieved the prespecified 70% consensus threshold, with 9 definitions reaching at least 90% agreement. After 2 electronic Delphi rounds, 16 of 18 guidance statements achieved the prespecified consensus threshold, with 13 statements receiving endorsement from more than 80% of participants. Two guidance statements related to assessment of tunneled plaques with multiple openings and assessment of scalp lesions failed to reach consensus. Conclusions and Relevance Common morphologic definitions and guidance that standardize assessment of HS lesions can be implemented in clinical trial protocols and investigator trainings with the goals of improving accuracy and reliability of investigator ratings.
Global consensus statement on the management of pregnancy in inflammatory bowel disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie D. , Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B.

Mayo Clinic

Gut | September 9, 2025 | Volume: 75 | Issue: 2 | Pages: 208-251

10.1136/gutjnl-2025-336402 | PMID 40876906 Get It

Background & aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 Consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda, Torres, Joana , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla, Long, Millie D. , IBD, Global Consensus Group for Pregnancy and, Maria, Abreu, Ali, Azzam Nahla, Wafaa, Badre, Rupa, Banerjee, Sally, Bell, Susan, Connor, Iris, D, Marc, Ferrante, Emily, Feneberg, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Juliao, Fabián, Leolin, Katsidzira, Alicia, Sambuelli, Christian, Selinger, Astrid, Williams, Jessica, L Thomson, Nicole, A. Capela, Wenli, Chen, Natalie, Hayden, Chun, Lin, Brosbol, Ravnborg Anne, Njeri, Mwaura-Ruhio Treza, Lindsay, Rous, Chaparro, María , Flanagan, Emma , Friedman, Sonia , Julsgaard, Mette , Ng, Siew C , Torres, Joana , Yamamoto-Furusho, Jesus , Barnes, Edward L , Friedman, Sonia , Ng, Siew C. , Robinson, Christopher James , Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Ali, Azzam Nahla, Marc, Ferrante, Emily, Finlayson, Ryota, Hokari, Vivian, Huang, Patricio, Ibanez, Wei, Shu‐Chen , Zaltman, Cyrla , Wenli, Chen, Lindsay, Rous

Mayo Clinic

Journal of Crohn’s and Colitis | September 7, 2025 | Volume: 19 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjaf129 | PMID 40914850 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L., Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L., Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 28, 2025 | Volume: 62 | Issue: 11-12 | Pages: 1125-1180

10.1111/apt.70290 | PMID 40874657 Get It

ABSTRACT Background & Aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High‐quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data‐driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla C. , Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

American Journal of Gastroenterology | August 27, 2025 | Volume: 121 | Issue: 1 | Pages: 31-79

10.14309/ajg.0000000000003651 | PMID 40862489 Get It

Introduction: Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods: The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results: The topics were divided into 10 categories with 34 GRADE recommendations and 35 Consensus statements. Discussion: Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Chaparro, María, Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan G. , Anderson, Phil, Duricova, Dana, Dubinsky, Marla C. , Long, Millie, IBD, Global Consensus Group for Pregnancy and, Barnes, Edward L, Chaparro, María, Kane, Sunanda, Ng, Siew, Fisher, Susan, Dubinsky, Marla, Long, Millie, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María, Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Fisher, Susan, Gearry, Richard B. , IBD, Global Consensus Group for Pregnancy and, Barnes, Edward L, Chaparro, María, Ng, Siew, Dubinsky, Marla, Long, Millie

Mayo Clinic

Inflammatory Bowel Diseases | July 15, 2025 | Volume: 31 | Issue: 10 | Pages: 2615-2664

10.1093/ibd/izaf171 | PMID 40874613 Get It

Abstract Background & Aims Pregnancy can be a complex and risk-filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND (Research and Development) process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Characterization of Portable Ultra‐Low Field MRI Scanners for Multi‐Center Structural Neuroimaging
Ljungberg, Emil , Padormo, Francesco , Poorman, Megan , Clemensson, Petter , Bourke, Niall , Evans, John , Gholam, James , Vavasour, Irene M. , Kolind, Shannon , Lafayette, Samson Lecurieux, Bennallick, Carly , Donald, Kirsten A. , Bradford, Layla E. , Lena, Beatrice , Vokhiwa, Maclean , Shama, Talat , Sekoli, Lydia, Rensburg, Janse van , Madhwani, Akber, Banda, Frank A., Mwila, Mwila L., Cassidy, Adam R. , Moabi, Kebaiphe, Sephi, Dolly, Boakye, Richard A. , Hollander, W. den, Karaulanov, Todor , Williams, Steven , Deoni, Sean , Evans, John C , Vavasour, Irene , Kollind, Shannon H , Pepper, Michael S , Cassidy, Adam R , Boakye, Richard A , Ae-Ngibise, Kenneth A , Asante, Kwaku P , Ljungberg, Emil , Bradford, Layla E. , Siew, Jasmine , Khan, Amna , Banda, Frank A., Hollander, William J.

Mayo Clinic

Human Brain Mapping | May 23, 2025 | Volume: 46 | Issue: 8 | Pages: No page available

10.1002/hbm.70217 | PMID 40405769 Get It

ABSTRACT The lower infrastructure requirements of portable ultra‐low field MRI (ULF‐MRI) systems have enabled their use in diverse settings such as intensive care units and remote medical facilities. The UNITY Project is an international neuroimaging network harnessing this technology, deploying portable ULF‐MRI systems globally to expand access to MRI for studies into brain development. Given the wide range of environments where ULF‐MRI systems may operate, there are external factors that might influence image quality. This work aims to introduce the quality control (QC) framework used by the UNITY Project to investigate how robust the systems are and how QC metrics compare between sites and over time. We present a QC framework using a commercially available phantom, scanned with 64 mT portable MRI systems at 17 sites across 12 countries on four continents. Using automated, open‐source analysis tools, we quantify signal‐to‐noise, image contrast, and geometric distortions. Our results demonstrated that the image quality is robust to the varying operational environment, for example, electromagnetic noise interference and temperature. The Larmor frequency was significantly correlated to room temperature, as was image noise and contrast. Image distortions were less than 2.5 mm, with high robustness over time. Similar to studies at higher field, we found that changes in pulse sequence parameters from software updates had an impact on QC metrics. This study demonstrates that portable ULF‐MRI systems can be deployed in a variety of environments for multi‐center neuroimaging studies and produce robust results.
Ethical Use of Cadaveric Images in Anatomical Textbooks, Atlases, and Journals: A Consensus Response From Authors and Editors
Kim, Hee‐Jin , Logan, Bari M., Hutchings, R. T., Anand, Mahindra , Burns, Danny, Singh, Vishram, Peris‐Celda, Maria , Martı́nez-Soriano, Francisco, Apaydın, Nihal, Hanna, Amgad S. , Yoshioka, Nobutaka , Fernandez‐Miranda, Juan C. , Saremi, Farhood , Spratt, Jonathan D., Ho, Siew Yen , Mori, Shumpei , Komune, Noritaka , Watanabe, Koichi , Abrahams, Peter, Ibaragi, Soichiro , Loukas, Marios , Tubbs, R. Shane, Kim, Hee-Jin , Hur, Mi-Sun , Reina, Francisco , Tabira, Yoko , Carrera, Anna , Komune, Noritaka , Watanabe, Koichi , Reina, Miguel Angel , Loukas, Marios , Iwanaga, Joe , Akita, Keiichi , Ottone, Nicolás Ernesto , Nonaka, Yoichi , Shoja, Mohammadali M. , Tabira, Yoko , Prats‐Galino, Alberto , Andrés, José De , Reina, Miguel Ángel , Anderson, Robert Henry

Mayo Clinic

Clinical Anatomy | January 4, 2025 | Volume: 38 | Issue: 2 | Pages: 222-225

10.1002/ca.24258 | PMID 39754475 Get It

ABSTRACT Nowadays, consent to use donor bodies for medical education and research is obtained from the body donors and their families before the donation. Recently, the International Federation of Associations of Anatomists (IFAA) published guidelines that could restrict the appearance of cadaveric images in commercial anatomical resources such as textbooks and other educational products. These guidelines state that the donor must expressly consent to using such images for this purpose. Cadaveric photos and drawings made from dissections of cadavers have been used in anatomy textbooks and atlases for hundreds of years. They are invaluable for anatomy students and clinical/surgical practitioners. The IFAA guidelines should not restrict the use of those older books; to do so would infringe the rights of those seeking knowledge from these resources. As the images in such textbooks and atlases are anonymized and are used for teaching and research, and the donors and their families are informed about this before the donation, we believe no additional consent is needed. It is impossible to separate educational from “commercial” usage entirely in any situation, e.g., publications from publishers and the use of cadavers in medical schools. Therefore, our best efforts to avoid unethical use of cadaveric images by following traditional consent processes are still needed so that more people will reap the benefits from them. As senior textbook/atlas authors/editors from over 10 countries, we believe that using cadaveric images in anatomy textbooks is appropriate, and no additional consent should be necessary. Such usage falls within the good faith of professionals using these invaluable gifts.